HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

Hope on the Horizon: A Game-Changing Approach to Early Breast Cancer Diagnosis

NextEdge Admin

14 Mar 2024

2 min 22 sec

In a groundbreaking development, geneticists from Hyderabad and Trivandrum have pioneered a non-invasive, cost-effective, and rapid blood test method for the early detection of breast cancer in women. Published in the February 2024 issue of Cell Communications and Signalling, a peer-reviewed journal by UK-based Biomed Central (BMC), the study focuses on utilizing miRNA signatures to identify potential biomarkers for the classification and early detection of Invasive Ductal Carcinoma (IDC), the most prevalent form of breast cancer, accounting for 80-85% of cases.

The collaboration between the Centre for Cellular and Molecular Biology (CCMB) in Hyderabad and the Regional Cancer Centre (RCC) in Trivandrum aims to alleviate the stigma and reluctance associated with physical breast examinations and mammography. Breast cancer has recently become the leading cause of cancer among women in India, with 1.9-2 lakh cases reported annually.

Analyzing 100 breast cancer samples, the researchers identified 34 novel miRNAs associated with IDC, demonstrating the method’s accuracy in differentiating cancer types, grades, and stages. The study marks a milestone as the first to unveil validated novel and signature miRNAs that could potentially serve as biomarkers for IDC across various cancer specifics.

This innovative approach promises a paradigm shift in breast cancer detection, offering a robust and efficient alternative to current diagnostic methods. The potential widespread adoption of this blood test could revolutionize early cancer detection, providing a critical tool in the fight against breast cancer and potentially saving countless lives.